SCHEMBL5451922

SCHEMBL5451922

CC(c1ccccc1)N1CCC(CN2C(=O)c3ccccc3C2=O)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ACHE P22303 2/20 0.46
HTT P42858 1/20 0.45
MAPT P10636 2/20 0.44
ALDH1A1 P00352 2/20 0.44
DUSP3 P51452 1/20 0.44
PTPN5 P54829 1/20 0.44
PTPN11 Q06124 1/20 0.44
CYP2D6 P10635 1/20 0.44
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
KDM4E B2RXH2 2/20 0.43
OPRM1 P35372 2/20 0.42
OPRK1 P41145 1/20 0.42
OPRL1 P41146 1/20 0.42
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
CCR5 P51681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14432037 1.00 LMNA (0.48) LMNASMN1; SMN2ACHEHTTMAPT
SCHEMBL5470865 0.83 ADRB2 (0.41) LMNASMN1; SMN2ACHEHTTMAPT
SCHEMBL7982300 0.81 DRD2 (0.58) SMN1; SMN2ACHEALDH1A1ADRB2ADRB1
SCHEMBL14026665 0.78 CYP2D6 (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL10280648 0.78 CYP2D6 (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL1713427 0.76 LMNA (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL879237 0.76 LMNA (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL7291562 0.76 LMNA (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL7459001 0.76 LMNA (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL5453145 0.76 LMNA (0.55) LMNASMN1; SMN2HTTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191333-A1 Antibacterial agents WARNER LAMBERT COMPANY LLC 2007-08-16 US disclosed
EP-1687296-A1 ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES Warner-Lambert Company LLC (US) 2006-08-09 EP disclosed
WO-2005049602-A1 QUINOLONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-06-02 WO disclosed
WO-2005049605-A1 ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191333-A1 Antibacterial agents MRPL21, RPN2, FBL LMNA 2919/4885SMN1; SMN2 2248/4885ACHE 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.